Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 2

Conditions

Neuroendocrine Tumors 394Multiple Endocrine Neoplasia Type 1 156Carcinoma, Neuroendocrine 123Thyroid Cancer, Papillary 118Pituitary Neoplasms 115Thyroid Neoplasms 100Pheochromocytoma 91Neoplasms 79Carcinoid Tumor 76Thyroid Carcinoma, Anaplastic 73Adrenocortical Carcinoma 73Paraganglioma 65Neoplasm Metastasis 56Adenocarcinoma, Follicular 53Carcinoma, Non-Small-Cell Lung 51Carcinoma, Medullary 50Insulinoma 49Pancreatic Neoplasms 47Adenoma, Islet Cell 47Colorectal Neoplasms 44Breast Neoplasms 44Small Cell Lung Carcinoma 42Sarcoma 42Gastro-enteropancreatic neuroendocrine tumor 42Carcinoma, Renal Cell 41Somatostatinoma 38Head and Neck Neoplasms 38Melanoma 37Lung Neoplasms 37Adrenal Gland Neoplasms 34

Interventions

AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Prostate Cancer × Endocrine × Clear all
NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed
41 enrolled 19 charts
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

NCT07024277 2025-06-17

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Not yet recruiting
60 enrolled
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡